William E. Barlow, PhD
Senior Investigator
206-287-2936
barlow.w@ghc.org
Recent publications
Curriculum vitae (CV)
Research interests and experience
- Biostatistics: case-cohort analysis; assessment of diagnostic tests; survival analysis
- Cancer control: biostatistics; breast cancer screening and treatment; mammography; molecular markers
- Alternative approaches to healing: biostatistics; acupuncture efficacy
- Women's health: breast cancer
Bill Barlow is a biostatistician with interests in outcomes of breast cancer screening and treatment.
Recent publications
Spangler L, Reid RJ, Newton KM, Chaudhari M, Inge R, Hujoel P, Genco R, Barlow WE. Using administrative data for epidemiologic research: case study to identify persons with periodontitis. Periodontol 2000. 2012 Feb;58(1):143-52. doi: 10.1111/j.1600-0757.2011.00422.x.
Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat. 2011 Nov;130(1):123-31. Epub 2011 Aug 9. PubMed
Fenton JJ, Abraham L, Taplin SH, Geller BM, Carney PA, D'Orsi C, Elmore JG, Barlow WE. Effectiveness of computer-aided detection in community mammography practice. J Natl Cancer Inst. 2011;103(15):1152-1161. Epub 2011 Jul 27. PubMed
Newton KM, Chaudhari M, Barlow WE, Inge RE, Theis MK, Spangler LA, Hujoel PP, Reid RJ. A population-based study of periodontal care among those with and without diabetes. J Periodontol. 2011 May 24. [Epub ahead of print]. PubMed
Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat. 2011 Apr;126(3):671-8. Epub 2010 Sep 3. PubMed
Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011 Mar 20;29(9):1221-7. Epub 2011 Feb 22. PubMed
Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011 Mar 10;29(8):1014-21. Epub 2011 Jan 10. PubMed
Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control. 2011 Mar;22(3):399-405. Epub 2010 Dec 24. PubMed
Janes H, Pepe MS, Bossuyt PM, Barlow WE. Measuring the performance of markers for guiding treatment decisions. Ann Intern Med. 2011;154(4):253-9. PubMed
Buist DS, Abraham LA, Barlow WE, Krishnaraj A, Holdridge RC, Sickles EA, Carney PA, Kerlikowske K, Geller BM. Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. Breast Cancer Res Treat. 2010 Dec;124(3):863-73. Epub 2010 Aug 11. PubMed
To view more publications, please see Dr. Barlow's CV.